12 Month Price Forecast For INSM
Distance to INSM Price Forecasts
INSM Price Momentum
๐ค Considering Insmed (INSM)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 12, 2025 12:08 AM UTC
INSM Analyst Ratings & Price Targets
Based on our analysis of 21 Wall Street analysts, INSM has a bullish consensus with a median price target of $90.00 (ranging from $67.26 to $105.00). The overall analyst rating is Strong Buy (9.4/10). Currently trading at $78.12, the median forecast implies a 15.2% upside. This outlook is supported by 17 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Nicole Germino at Truist Securities, projecting a 34.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
INSM Analyst Consensus
INSM Price Target Range
Latest INSM Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for INSM.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Feb 7, 2025 | JP Morgan | Jessica Fye | Overweight | Maintains | $92.00 |
Feb 7, 2025 | Guggenheim | Vamil Divan | Buy | Maintains | $101.00 |
Feb 6, 2025 | Morgan Stanley | Matthew Harrison | Overweight | Maintains | $90.00 |
Nov 22, 2024 | JP Morgan | Jessica Fye | Overweight | Maintains | $83.00 |
Nov 1, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $90.00 |
Nov 1, 2024 | Truist Securities | Nicole Germino | Buy | Reiterates | $105.00 |
Oct 11, 2024 | Truist Securities | Nicole Germino | Buy | Maintains | $100.00 |
Oct 9, 2024 | B of A Securities | Jason Zemansky | Buy | Maintains | $86.00 |
Oct 3, 2024 | JP Morgan | Jessica Fye | Overweight | Maintains | $74.00 |
Sep 9, 2024 | Cantor Fitzgerald | Josh Schimmer | Overweight | Reiterates | $0.00 |
Aug 29, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $90.00 |
Aug 12, 2024 | Truist Securities | Nicole Germino | Buy | Maintains | $85.00 |
Aug 12, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $90.00 |
Aug 9, 2024 | Stifel | Stephen Willey | Buy | Maintains | $88.00 |
Aug 9, 2024 | TD Cowen | Ritu Baral | Buy | Maintains | $98.00 |
Aug 9, 2024 | UBS | Trung Huynh | Buy | Maintains | $84.00 |
Jul 12, 2024 | Morgan Stanley | Matthew Harrison | Overweight | Maintains | $85.00 |
Jul 10, 2024 | Goldman Sachs | Andrea Tan | Buy | Maintains | $102.00 |
Jul 9, 2024 | Guggenheim | Vamil Divan | Buy | Maintains | $95.00 |
Jul 8, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Maintains | $90.00 |
Stocks Similar to Insmed Inc
The following stocks are similar to Insmed based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Insmed Inc (INSM) Financial Data
Insmed Inc has a market capitalization of $14.03B with a P/E ratio of -15.0x. The company generates $342.96M in trailing twelve-month revenue with a -252.0% profit margin.
Revenue growth is +18.2% quarter-over-quarter, while maintaining an operating margin of -212.7% and return on equity of -890.7%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

Insmed Inc (INSM) Company Overview
About Insmed Inc
Develops therapies for serious rare diseases.
Insmed Incorporated operates as a biopharmaceutical company focusing on the development and commercialization of treatments for serious and rare diseases. The company generates revenue primarily through the sales of its approved therapy ARIKAYCE, while also investing in the research and development of additional products like Brensocatib and Treprostinil Palmitil Inhalation Powder to diversify its portfolio and address various unmet medical needs.
Founded in 1988 and headquartered in Bridgewater, New Jersey, Insmed is actively expanding its presence in the United States, Europe, Japan, and other international markets, aiming to improve patient outcomes for those suffering from challenging health conditions.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
912
CEO
Mr. William H. Lewis J.D., M.B.A.
Country
United States
IPO Year
2000
Website
www.insmed.comInsmed Inc (INSM) Latest News & Analysis
Insmed Incorporated (Nasdaq: INSM) will announce its Q4 and full-year 2024 financial results on February 20, 2025.
The announcement of Insmed's Q4 and full-year 2024 financial results can significantly impact stock performance and investor sentiment, reflecting the company's growth and operational health.
Insmed's brensocatib has received FDA acceptance for its New Drug Application, potentially becoming the first treatment for non-cystic fibrosis bronchiectasis and the first DPP1 inhibitor.
Approval of brensocatib could position Insmed as a market leader in treating bronchiectasis, potentially driving revenue growth and stock value due to lack of competition.
Insmed Incorporated (Nasdaq: INSM) announced the granting of inducement awards to 66 new employees, indicating ongoing growth and investment in talent.
Insmed's inducement awards signal growth and investment in talent, indicating potential expansion and innovation, which can positively influence stock performance and investor confidence.
The FDA has accepted INSM's NDA for brensocatib for non-cystic fibrosis bronchiectasis and granted priority review, with a decision expected by August 12, 2025.
The FDA's priority review of INSM's brensocatib signals potential faster market entry, impacting revenue projections and stock performance ahead of the 2025 decision.
Insmed's Arikayce earned $93.4m in Q3 2023, with full-year guidance of $340m-$360m. Brensocatib received FDA Priority Review, with peak annual revenue projections over $5bn. Market cap: $14.45bn.
Insmed's strong Q3 revenue from Arikayce and promising FDA review for Brensocatib highlight growth potential, likely driving investor confidence and supporting stock performance.
Insmed forecasts 2024 global ARIKAYCE revenues at $363.7M and expects 2025 revenues between $405M-$425M. Key clinical developments include a new drug application and ongoing trials with data expected in 2025-2026.
Strong revenue growth for ARIKAYCE and upcoming product launches signal positive momentum for Insmed, potentially enhancing investor confidence and stock value.
Frequently Asked Questions About INSM Stock
What is Insmed Inc's (INSM) stock forecast for 2025?
Based on our analysis of 21 Wall Street analysts, Insmed Inc (INSM) has a median price target of $90.00. The highest price target is $105.00 and the lowest is $67.26.
Is INSM stock a good investment in 2025?
According to current analyst ratings, INSM has 17 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $78.12. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for INSM stock?
Wall Street analysts predict INSM stock could reach $90.00 in the next 12 months. This represents a 15.2% increase from the current price of $78.12. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Insmed Inc's business model?
Insmed Incorporated operates as a biopharmaceutical company focusing on the development and commercialization of treatments for serious and rare diseases. The company generates revenue primarily through the sales of its approved therapy ARIKAYCE, while also investing in the research and development of additional products like Brensocatib and Treprostinil Palmitil Inhalation Powder to diversify its portfolio and address various unmet medical needs.
What is the highest forecasted price for INSM Insmed Inc?
The highest price target for INSM is $105.00 from Nicole Germino at Truist Securities, which represents a 34.4% increase from the current price of $78.12.
What is the lowest forecasted price for INSM Insmed Inc?
The lowest price target for INSM is $67.26 from at , which represents a -13.9% decrease from the current price of $78.12.
What is the overall INSM consensus from analysts for Insmed Inc?
The overall analyst consensus for INSM is bullish. Out of 21 Wall Street analysts, 17 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $90.00.
How accurate are INSM stock price projections?
Stock price projections, including those for Insmed Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.